Corneal Ulcer Treatment Market Will Rise at a CAGR of 5.7% CAGR 2022 – 2029

Increasing contact lens usage, emerging new treatment options such as anti-amoebic drugs, and well-established supply chain operations are expected to fuel the growth of the corneal ulcer treatment market.

Various initiatives by global as well as regional organizations, governments, etc., to eliminate avoidable blindness caused due to contact lens use, are helping to increase awareness about corneal ulcer among the general public as well as ophthalmologists.

Further, universities and non-profit organizations arranging eye check-up camps further aids in enhancing awareness about corneal ulcers.

Request a sample of this report @

 https://www.futuremarketinsights.com/reports/sample/rep-gb-6953 

FMI – a well-established name in the market research domain – forecasts that, the corneal ulcer treatment market will experience a major upturn in the coming years, reaching a valuation of US$ 1.27 Bn by 2029.

Key Takeaways of Corneal Ulcer Treatment Market Study

• Treatment of broad-spectrum corneal ulcers using antibiotics is expected to gain traction and contribute more than 75% of revenue share during the forecast period.
• Growing bacterial keratitis requiring antibiotics for treatment will contribute significantly to the revenue share of the segment.
• Eye drops or eye ointments dominate the market by form type, as these are relatively cheaper and do not require other interventional and oral route for drug delivery.
• By distribution channel, retail pharmacies are expected to gain more than 50% of market share during the forecast period.
• North America is dominating the global corneal ulcer treatment market, while East Asia is expected to offer lucrative growth opportunities, owing to rising healthcare infrastructure and industrialization.

Acquisition – Key Strategy Followed by Leading Manufacturers

Leading manufacturers in the corneal ulcer treatment market are focusing on geographical expansion as well as increased product offerings through partnerships and acquisitions.

In order to evaluate cost effective therapy for corneal ulcer treatment, manufacturers are evaluating new drugs via clinical trials For example, in Dec. 2019, Mallinckrodt plc enrolled the first patient in the company’s Phase 4, multi-center, multiple-dose, open-label study to assess the effects of Acthar Gel as a therapy option in patients with severe keratitis.

 Request TOC @ 

https://www.futuremarketinsights.com/toc/rep-gb-6953 

Related Reports –

https://medium.com/@ashufmi/minimally-invasive-lung-cancer-surgery-trends-industry-analysis-2029-42aebf57558

https://hackmd.io/@Ashish119/H1ZrRhRP9

https://beyondher.mn.co/posts/23796255?utm_source=manual

https://community.telegramfxcopier.io/post/minimally-invasive-lung-cancer-surgery-worldwide-industry-analysis-and-new—6291427925e680a51e6bbc19

https://kgn.tribe.so/post/minimally-invasive-lung-cancer-surgery-worldwide-industry-analysis-and-new—6291427e25e6800b6d6bbc1b

About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.

It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years

Contact Us:

Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers, Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs